Related Experiment Videos
Luteinizing hormone-releasing hormone antagonists in prostate cancer
1Department of Urology, Henry Ford Hospital, Detroit, Michigan 48202, USA. hstrick1@hfhs.org
Abstract:
Luteinizing hormone-releasing hormone (LHRH) antagonists work by directly inhibiting LHRH without any initial stimulation of the LHRH receptor. The physiologic response is a direct and rapid decrease in luteinizing hormone, follicle-stimulating hormone, and testosterone without any flare. Although there has been extensive basic-science work on these medications, practical shortcomings have limited clinical studies in prostate cancer. Many of these compounds induce significant histamine-mediated side effects, and until recently, no depot form existed. In 2 recent phase-3 studies comparing abarelix depot with leuprolide and with leuprolide plus bicalutamide, abarelix lowered serum testosterone more quickly. None of the 89 patients on leuprolide alone were castrate on day 8 as opposed to 72% of the 180 patients randomized to abarelix (P <0.001). Similarly, none of the combination group were castrate by day 8, whereas 68% of the abarelix patients were castrate (P <0.001). In addition, 82% of the patients treated with leuprolide and 86% of those given leuprolide/bicalutamide had testosterone surge, whereas none of the abarelix patients did (P <0.001 for both studies). Both phase 2 and phase 3 data show abarelix to be well tolerated. In conclusion, LHRH antagonists offer the physiologic response of orchiectomy without surgery. These medications are well tolerated and a depot form now exists. The expansion of indications for androgen deprivation, such as downsizing or intermittent therapy, could provide many opportunities for their use. Despite these encouraging advances, however, their routine use for advanced prostate cancer may depend on demonstration of a survival advantage in avoiding flare.
Insights
Luteinizing hormone-releasing hormone (LHRH) antagonists rapidly decrease testosterone without a flare, offering an alternative to surgical castration for prostate cancer. Abarelix depot demonstrated faster testosterone reduction and fewer side effects in clinical trials.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Luteinizing hormone-releasing hormone (LHRH) antagonists offer direct inhibition of LHRH, leading to rapid testosterone reduction without the initial flare seen with other therapies.
- Practical challenges, including histamine-mediated side effects and lack of a depot formulation, have historically limited the clinical application of LHRH antagonists in prostate cancer.
- Recent advancements have addressed these limitations, with the development of depot formulations and improved tolerability profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of abarelix depot, a novel LHRH antagonist, in achieving rapid and sustained testosterone suppression in patients with advanced prostate cancer.
- To compare the onset and degree of testosterone suppression between abarelix depot and traditional LHRH agonists (leuprolide).
- To assess the incidence of testosterone flare and associated side effects in patients treated with abarelix depot versus leuprolide.
Main Methods:
- Two Phase 3 clinical trials were conducted, comparing abarelix depot to leuprolide alone and to leuprolide in combination with bicalutamide.
- Serum testosterone levels were monitored to assess the rate and extent of castration.
- Incidence of testosterone flare and treatment-emergent adverse events were recorded and compared between treatment arms.
Main Results:
- Abarelix depot achieved significantly faster serum testosterone reduction compared to leuprolide. On day 8, 72% of patients on abarelix depot achieved castration, versus 0% on leuprolide alone (P < 0.001).
- In the combination study, 68% of patients on abarelix depot were castrate by day 8, compared to 0% in the leuprolide plus bicalutamide arm (P < 0.001).
- Testosterone flare was observed in 82-86% of patients on leuprolide-based regimens, whereas no flare occurred in patients receiving abarelix depot (P < 0.001 for both studies). Abarelix depot was well tolerated.
Conclusions:
- LHRH antagonists, exemplified by abarelix depot, provide a non-surgical option for achieving the physiological effects of orchiectomy.
- The availability of a depot formulation and demonstrated tolerability enhance the clinical utility of LHRH antagonists.
- Further research is warranted to establish a survival advantage for LHRH antagonists in advanced prostate cancer, particularly in the context of avoiding testosterone flare and exploring intermittent androgen deprivation strategies.